ZAI LAB LIMITED Revenue from Contract with Customer, Excluding Assessed Tax
ZAI LAB LIMITED (ZLAB) reported Revenue from Contract with Customer, Excluding Assessed Tax of $105.75 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- ZAI LAB LIMITED revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $105.75M, a 3.06% decline year-over-year.
- ZAI LAB LIMITED revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $95.56M, a 9.55% decline year-over-year.
- ZAI LAB LIMITED revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $127.09M, a 17.12% increase year-over-year.
- ZAI LAB LIMITED revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $115.36M, a 13.27% increase year-over-year.
- ZAI LAB LIMITED revenue from contract with customer, excluding assessed tax for fiscal 2025 was $457.18M, a 14.98% increase from fiscal 2024.
- ZAI LAB LIMITED revenue from contract with customer, excluding assessed tax for fiscal 2024 was $397.61M, a 49.08% increase from fiscal 2023.
- ZAI LAB LIMITED revenue from contract with customer, excluding assessed tax for fiscal 2023 was $266.72M, a 25.41% increase from fiscal 2022.
- ZAI LAB LIMITED revenue from contract with customer, excluding assessed tax for fiscal 2022 was $212.67M, a 47.58% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $105.75M 10-Q · filed 2026-08-06 | $201.31M 10-Q · filed 2026-08-06 | $328.39M derived: sum of 3 quarters · filed 2026-08-06 | $443.75M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $95.56M 10-Q · filed 2026-05-07 | $222.64M derived: sum of 2 quarters · filed 2026-05-07 | $338.00M derived: sum of 3 quarters · filed 2026-05-07 | $447.09M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $127.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $242.45M derived: sum of 2 quarters · filed 2026-02-26 | $351.53M derived: sum of 3 quarters · filed 2026-08-06 | $457.18M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $115.36M 10-Q · filed 2025-11-06 | $224.45M derived: sum of 2 quarters · filed 2026-08-06 | $330.10M 10-Q · filed 2025-11-06 | $438.61M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $109.08M 10-Q · filed 2026-08-06 | $214.74M 10-Q · filed 2026-08-06 | $323.25M derived: sum of 3 quarters · filed 2026-08-06 | $425.09M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $105.65M 10-Q · filed 2026-05-07 | $214.16M derived: sum of 2 quarters · filed 2026-05-07 | $316.01M derived: sum of 3 quarters · filed 2026-05-07 | $416.12M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $108.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $210.36M derived: sum of 2 quarters · filed 2026-02-26 | $310.46M derived: sum of 3 quarters · filed 2026-02-26 | $397.61M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $101.85M 10-Q · filed 2025-11-06 | $201.95M derived: sum of 2 quarters · filed 2025-11-06 | $289.10M 10-Q · filed 2025-11-06 | $354.93M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $100.11M 10-Q · filed 2025-08-07 | $187.25M 10-Q · filed 2025-08-07 | $253.09M derived: sum of 3 quarters · filed 2026-02-26 | $322.31M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $87.15M 10-Q · filed 2025-05-08 | $152.98M derived: sum of 2 quarters · filed 2026-02-26 | $222.21M derived: sum of 3 quarters · filed 2026-02-26 | $291.07M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $65.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $135.06M derived: sum of 2 quarters · filed 2026-02-26 | $203.92M derived: sum of 3 quarters · filed 2026-02-26 | $266.72M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $69.23M 10-Q · filed 2024-11-12 | $138.09M derived: sum of 2 quarters · filed 2024-11-12 | $200.89M 10-Q · filed 2024-11-12 | $262.93M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | $68.86M 10-Q · filed 2024-08-06 | $131.66M 10-Q · filed 2024-08-06 | $193.70M derived: sum of 3 quarters · filed 2025-02-27 | $250.66M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | $62.80M 10-Q · filed 2024-05-08 | $124.84M derived: sum of 2 quarters · filed 2025-02-27 | $181.80M derived: sum of 3 quarters · filed 2025-02-27 | $229.37M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | $62.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $119.00M derived: sum of 2 quarters · filed 2025-02-27 | $166.58M derived: sum of 3 quarters · filed 2025-02-27 | $212.67M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $56.96M 10-Q · filed 2023-11-07 | $104.54M derived: sum of 2 quarters · filed 2023-11-07 | $150.63M 10-Q · filed 2023-11-07 | $194.60M derived: sum of 4 quarters · filed 2023-11-07 | |
| 2022-06-30 | $47.58M 10-Q · filed 2023-08-07 | $93.67M 10-Q · filed 2023-08-07 | $137.63M derived: sum of 3 quarters · filed 2023-08-07 | $180.74M derived: sum of 4 quarters · filed 2023-08-07 | |
| 2022-03-31 | $46.09M 10-Q · filed 2023-05-09 | $90.06M derived: sum of 2 quarters · filed 2023-05-09 | $133.16M derived: sum of 3 quarters · filed 2023-05-09 | $170.10M derived: sum of 4 quarters · filed 2023-05-09 | |
| 2021-12-31 | $43.96M 10-K · filed 2022-03-01 | $87.07M derived: sum of 2 quarters · filed 2022-11-09 | $124.00M derived: sum of 3 quarters · filed 2022-11-09 | $144.10M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $43.10M 10-Q · filed 2022-11-09 | $80.04M derived: sum of 2 quarters · filed 2022-11-09 | $100.14M 10-Q · filed 2022-11-09 | $115.23M derived: sum of 4 quarters · filed 2022-11-09 | |
| 2021-06-30 | $36.94M 10-Q · filed 2022-08-09 | $57.04M 10-Q · filed 2022-08-09 | $72.13M derived: sum of 3 quarters · filed 2022-08-09 | $86.78M derived: sum of 4 quarters · filed 2022-08-09 | |
| 2021-03-31 | $20.10M 10-Q · filed 2022-05-10 | $35.20M derived: sum of 2 quarters · filed 2022-05-10 | $49.85M derived: sum of 3 quarters · filed 2022-05-10 | $60.84M derived: sum of 4 quarters · filed 2022-05-10 | |
| 2020-12-31 | $15.09M 10-K · filed 2022-03-01 | $29.75M derived: sum of 2 quarters · filed 2022-03-01 | $40.74M derived: sum of 3 quarters · filed 2022-03-01 | $48.96M 10-K · filed 2023-03-01 | |
| 2020-09-30 | $14.65M 10-K · filed 2022-03-01 | $25.65M derived: sum of 2 quarters · filed 2022-03-01 | $33.86M 10-Q · filed 2021-11-09 | $38.51M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-06-30 | $10.99M 10-K · filed 2022-03-01 | $19.21M 10-Q · filed 2021-08-09 | $23.86M derived: sum of 3 quarters · filed 2022-03-01 | $28.78M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-03-31 | $8.22M 10-K · filed 2022-03-01 | $12.86M derived: sum of 2 quarters · filed 2022-03-01 | $17.78M derived: sum of 3 quarters · filed 2022-03-01 | ||
| 2019-12-31 | $4.65M derived: 10-K 12 month − 6-K 9 month · filed 2022-03-01 | $9.56M derived: sum of 2 quarters · filed 2022-03-01 | $12.98M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | $4.92M derived: 6-K 9 month − 6-K 6 month · filed 2020-01-21 | $8.34M 6-K · filed 2020-01-21 | |||
| 2019-06-30 | $3.42M 6-K · filed 2020-09-11 | ||||
| 2018-12-31 | $129.00K 10-K · filed 2021-03-01 | $129.45K 20-F · filed 2019-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |